Abstract

BackgroundNa+/I- symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer. NIS is also expressed in breast tumors, raising potential for radionuclide therapy of breast cancer. However, NIS expression in most breast cancers is low and may not be sufficient for radionuclide therapy. We aimed to identify biomarkers associated with NIS expression such that mechanisms underlying NIS modulation in human breast tumors may be elucidated.MethodsPublished oligonucleotide microarray data within the National Center for Biotechnology Information Gene Expression Omnibus database were analyzed to identify gene expression tightly correlated with NIS mRNA level among human breast tumors. NIS immunostaining was performed in a tissue microarray composed of 28 human breast tumors which had corresponding oligonucleotide microarray data available for each tumor such that gene expression associated with cell surface NIS protein level could be identified.Results and DiscussionNIS mRNA levels do not vary among breast tumors or when compared to normal breast tissues when detected by Affymetrix oligonucleotide microarray platforms. Cell surface NIS protein levels are much more variable than their corresponding NIS mRNA levels. Despite a limited number of breast tumors examined, our analysis identified cysteinyl-tRNA synthetase as a biomarker that is highly associated with cell surface NIS protein levels in the ER-positive breast cancer subtype.ConclusionsFurther investigation on genes associated with cell surface NIS protein levels within each breast cancer molecular subtype may lead to novel targets for selectively increasing NIS expression/function in a subset of breast cancers patients.

Highlights

  • Na+/I- symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer

  • Further investigation on genes associated with cell surface NIS protein levels within each breast cancer molecular subtype may lead to novel targets for selectively increasing NIS expression/function in a subset of breast cancers patients

  • NIS mRNA levels detected by HG U133A oligonucleotide microarray (NIS probe set ID 211123_at) do not vary among breast tumors or when compared to normal breast tissue NIS expression among breast tumors within the GSE3744 dataset [17] was detected by the 211123_at NIS probe set on the Affymetrix HG-U133 Plus 2.0

Read more

Summary

Introduction

Na+/I- symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer. NIS is expressed in breast tumors, raising potential for radionuclide therapy of breast cancer. We aimed to identify biomarkers associated with NIS expression such that mechanisms underlying NIS modulation in human breast tumors may be elucidated. NIS is induced in the breast during lactation to accumulate iodide for the nursing infant to synthesize its own thyroid hormones [1,2]. NIS has been detected in the majority of breast tumors, raising promise for radionuclide therapy of breast cancer [3,4,5,6]. Only a minority of NIS-positive breast tumors had detectable radionuclide accumulation [4,5,6], Mechanisms underlying NIS modulation in human breast cancer are poorly understood. A combination of tRA and hydrocortisone (tRA/H), further increases tRA-induced NIS expression/

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call